Resolution of DOJ Investigation Involving Medical Device Manufacturer

ArthroCare Corporation agreed to pay $30 million and entered into a deferred prosecution agreement to end a five-year U.S. Department of Justice (DOJ) securities fraud investigation into whether senior executives defrauded investors. The $30 million represented an almost 50% reduction of the amount of fine that could have been levied against the company under the U.S. Sentencing Guidelines due to its extensive remedial and cooperation efforts. Further, the DOJ did not require a monitor.

ArthroCare Corporation (NASDAQ: ARTC) develops and manufactures surgical devices, instruments, and implants that strive to enhance surgical techniques as well as improve patient outcomes.

You Also May Be Interested In:

  • We represented BioScrip, Inc. in its merger with Option Care Enterprises, Inc. The newly combined company, Option Care Health, Inc., emerges as the largest independent home and alternate site infusion services provider in the United States. Option Care Health’s common stock will be listed on the Nasdaq Global Select Market under the ticker symbol BIOS.

     

    We represented BioScrip, Inc. in its merger with Option Care Enterprises, Inc. The newly combined company, Option Care Health, Inc.,...
    Client Type: Public Company
  • Successfully represented a private equity backed portfolio provider and its management company in a voluntary disclosure to HHS-OIG involving improper billing

    We successfully represented a private equity backed portfolio provider and its management company in a voluntary disclosure to the Department...
  • Obtained a jury trial victory on six of seven counts for the former vice president of Pilot Flying J who, along with three others, was accused of seeking to defraud customers

    Bass, Berry & Sims obtained a jury trial victory on six of seven counts for the former vice president of...